MedTrace Logo

Phase II Dose Titration Study in Patients With Neuropathic Pain

NCT00736151 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2009-08-07

No results posted yet for this study

Summary

The purpose of this study is to examine the effects of various increasing doses of Ralfinamide in patients with neuropathic pain.

Conditions

  • Neuropathic Pain

Interventions

DRUG

Ralfinamide

Oral tablets administered at rising doses of 80 - 320 mg/day

Sponsors & Collaborators

  • Newron Pharmaceuticals SPA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2007-04-30

Countries

  • Austria
  • Czechia
  • India
  • Italy
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736151 on ClinicalTrials.gov